Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
University of Latvia
5,000 participants
Nov 1, 2019
OBSERVATIONAL
Conditions
Summary
The study is aimed to determine the potential of volatile marker testing for gastric cancer screening. The study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.
Eligibility
Inclusion Criteria6
- Patients with verified gastric cancer (Group 1 \& 2)
- Patients undergoing or having undergone upper endoscopy according to clinical indications (Group 3 \& 5)
- Average-risk population group aged 40-64 at inclusion without alarm symptoms (Group 4)
- Motivation to participate in the study
- Physical status allowing volatile marker sampling and other procedures within the protocol
- Signed consent
Exclusion Criteria3
- Known other active cancer
- Ventilation problems, airway obstruction
- Unwillingness or inability to co-operate
Interventions
Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
Only for gastric cancer patients undergoing surgery (Group 1)
Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
Faecal and gastric contents and biopsy samples for microbiota testing
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04022109